Clinical effect of telmisartan combined with simvastatin in treatment of early diabetic nephropathy
10.3760/cma.j.issn.1008-6706.2011.18.008
- VernacularTitle:替米沙坦联合辛伐他汀治疗糖尿病肾病疗效观察
- Author:
Xiaoyun CHEN
;
Jianzhong XU
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathy;
Telmisartan;
Simvastatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2011;18(18):2463-2465
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the clinical efficacy and safty of combined treatment telmisartan plus simvastatin on early diabetic nephropathy. Methods46 patients with early diabetic nephropathy were randomly divided into two groups. Control group ( n = 23 ) received regular insulin therapy, captopril l0mg tid. Study group received telmisartan 80mg qd plus simvastatin 20mg qd on the basis of control group therapy. All patients received 16 weeks treatment. The clinical parameters were measured before and after therapy. ResultsAfter 16 weeks treatment,the urine MAU in both study group and control group were significantly decreased( all P <0. 01 ) ,however,the urine MAU in telmisartan plus simvastatin combination group decreased significantly than control group( P < 0. 01 ). Improvement of lipid level in the study group better than the control group( P <0. 01 ). Kidney function,fasting blood glucose levels and HbAlc had no significant changes before and after treatment. ConclusionTelmisartan plus simvastatin combined treatment was better than the traditional therapy,which can delay the development of early diabetic nephropathy.